SCHEMBL20535909

SCHEMBL20535909

CC(C)CNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 9/20 0.79
CYP1A2 P05177 8/20 0.79
CYP2C8 P10632 6/20 0.79
CYP2C19 P33261 6/20 0.79
KCNH2 Q12809 5/20 0.79
CYP2C9 P11712 4/20 0.79
CYP3A4 P08684 3/20 0.79
APP P05067 3/20 0.67
NR4A2 P43354 3/20 0.67
ABCB11 O95342 1/20 0.67
CHRM2 P08172 1/20 0.67
HTR1A P08908 1/20 0.67
CHRM1 P11229 1/20 0.67
DRD2 P14416 1/20 0.67
ADRA2C P18825 1/20 0.67
SLC6A2 P23975 1/20 0.67
PTGS2 P35354 1/20 0.67
OPRM1 P35372 1/20 0.67
HTR2B P41595 1/20 0.67
CYP2J2 P51589 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Desethyl Amodiaquine SCHEMBL30544257 0.89 CYP2D6 (1.00) CYP2D6CYP1A2CYP2C8CYP2C19KCNH2
Desethyl Amodiaquine SCHEMBL14067597 0.89 CYP2D6 (1.00) CYP2D6CYP1A2CYP2C8CYP2C19KCNH2
SCHEMBL20536208 0.88 CYP2D6 (0.61) CYP2D6CYP1A2CYP2C8CYP2C19KCNH2
SCHEMBL20536225 0.87 CYP2D6 (0.84) CYP2D6CYP1A2CYP2C8CYP2C19KCNH2
SCHEMBL21840686 0.86 CYP2D6 (0.79) CYP2D6CYP1A2CYP2C8CYP2C19KCNH2
Desethyl Amodiaquine SCHEMBL31276886 0.85 CYP2D6 (0.78) CYP2D6CYP1A2CYP2C8CYP2C19KCNH2
SCHEMBL20536213 0.85 CYP2D6 (0.74) CYP2D6CYP1A2CYP2C8CYP2C19KCNH2
N-Tert-Butyl-Amodiaquine SCHEMBL21840688 0.84 CYP2D6 (0.84) CYP2D6CYP1A2CYP2C8CYP2C19KCNH2
SCHEMBL20536661 0.84 CYP2D6 (0.80) CYP2D6CYP1A2CYP2C8CYP2C19KCNH2
SCHEMBL20536547 0.84 CYP2D6 (0.76) CYP2D6CYP1A2CYP2C8CYP2C19KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11571416-B2 Amodiaquine analogs and methods of uses thereof KAGOSHIMA UNIVERSITY (JP) 2023-02-07 US disclosed
US-20200113891-A1 NOVEL AMODIAQUINE ANALOGS AND METHODS OF USES THEREOF KAGOSHIMA UNIVERSITY (JP) 2020-04-16 US disclosed
WO-2018191642-A1 NOVEL AMODIAQUINE ANALOGS AND METHODS OF USES THEREOF TEXAS BIOMEDICAL RESEARCH INSTITUTE (US) 2018-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11571416-B2 Amodiaquine analogs and methods of uses thereof HAVCR2, SARS1, XPA CYP2D6 881/4885CYP1A2 1853/4885CYP2C8 1578/4885
US-20200113891-A1 NOVEL AMODIAQUINE ANALOGS AND METHODS OF USES THEREOF HAVCR2, SARS1, XPA CYP2D6 914/4885CYP1A2 2192/4885CYP2C8 1744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.